CX-2009

DB16090InvestigationalProtein Based Therapies

CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

Mechanism: Pharmacologically active on CD166 antigen
Curator reviewed
Also known as: Anti-cd166 probody-drug conjugate cx-2009 · Praluzatamab ravtansine
Code names: ANTI-CD166-DM4 CX-2009 · CX-2009

Resolves to

Compound

UNIIRD2I59M9FCCAS2145115-85-9

Targets

Q13740ALCAM

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CX-2009, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account